Selected research
Industry Research
Anti-Infective Vaccines Industry Research Report 2026
Market perspective
The global Anti-Infective Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anti-Infective Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anti-Infective Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anti-Infective Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anti-Infective Vaccines include Sanofi Pasteur, Novartis Vaccines, Merck & Co., GlaxoSmithKline Biologicals, Wyeth Pharmaceuticals, Inc., Protein Sciences Co., Organon Teknika Co., MedImmune LLC and MassBiologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anti-Infective Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Infective Vaccines Market by Company
Sanofi Pasteur
Novartis Vaccines
Merck & Co.
GlaxoSmithKline Biologicals
Wyeth Pharmaceuticals, Inc.
Protein Sciences Co.
Organon Teknika Co.
MedImmune LLC
MassBiologics
Intercell Biomedical
ID Biomedical Co.
Emergent BioDefense Operations Lansing Inc.
Diagnostics Ltd.
CSL Ltd.
Berna Biotech
Barr Labs, Inc.
Anti-Infective Vaccines Segment by Type
Inactivated Vaccines
Live/attenuated Vaccines
Conjugate Vaccines
Anti-Infective Vaccines Segment by Application
Bacterial Diseases
Viral Diseases
Anti-Infective Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Infective Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Infective Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Infective Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-Infective Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-Infective Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-Infective Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inactivated Vaccines
- Live/attenuated Vaccines
- Conjugate Vaccines
Applications
- Bacterial Diseases
- Viral Diseases
Companies covered
- Sanofi Pasteur
- Novartis Vaccines
- Merck & Co.
- GlaxoSmithKline Biologicals
- Wyeth Pharmaceuticals, Inc.
- Protein Sciences Co.
- Organon Teknika Co.
- MedImmune LLC
- MassBiologics
- Intercell Biomedical
- ID Biomedical Co.
- Emergent BioDefense Operations Lansing Inc.
- Diagnostics Ltd.
- CSL Ltd.
- Berna Biotech
- Barr Labs, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-Infective Vaccines Market Size (2021-2032)
- 2.2.2 Global Anti-Infective Vaccines Sales (2021-2032)
- 2.2.3 Global Anti-Infective Vaccines Market Average Price (2021-2032)
- 2.3 Anti-Infective Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Inactivated Vaccines
- 2.3.3 Live/attenuated Vaccines
- 2.3.4 Conjugate Vaccines
- 2.4 Anti-Infective Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Bacterial Diseases
- 2.4.3 Viral Diseases
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-Infective Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-Infective Vaccines Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Anti-Infective Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-Infective Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-Infective Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-Infective Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-Infective Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Anti-Infective Vaccines, Established Date
- 3.9 Global Anti-Infective Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi Pasteur
- 4.1.1 Sanofi Pasteur Company Information
- 4.1.2 Sanofi Pasteur Business Overview
- 4.1.3 Sanofi Pasteur Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Pasteur Anti-Infective Vaccines Product Portfolio
- 4.1.5 Sanofi Pasteur Recent Developments
- 4.2 Novartis Vaccines
- 4.2.1 Novartis Vaccines Company Information
- 4.2.2 Novartis Vaccines Business Overview
- 4.2.3 Novartis Vaccines Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Vaccines Anti-Infective Vaccines Product Portfolio
- 4.2.5 Novartis Vaccines Recent Developments
- 4.3 Merck & Co.
- 4.3.1 Merck & Co. Company Information
- 4.3.2 Merck & Co. Business Overview
- 4.3.3 Merck & Co. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck & Co. Anti-Infective Vaccines Product Portfolio
- 4.3.5 Merck & Co. Recent Developments
- 4.4 GlaxoSmithKline Biologicals
- 4.4.1 GlaxoSmithKline Biologicals Company Information
- 4.4.2 GlaxoSmithKline Biologicals Business Overview
- 4.4.3 GlaxoSmithKline Biologicals Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GlaxoSmithKline Biologicals Anti-Infective Vaccines Product Portfolio
- 4.4.5 GlaxoSmithKline Biologicals Recent Developments
- 4.5 Wyeth Pharmaceuticals, Inc.
- 4.5.1 Wyeth Pharmaceuticals, Inc. Company Information
- 4.5.2 Wyeth Pharmaceuticals, Inc. Business Overview
- 4.5.3 Wyeth Pharmaceuticals, Inc. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Wyeth Pharmaceuticals, Inc. Anti-Infective Vaccines Product Portfolio
- 4.5.5 Wyeth Pharmaceuticals, Inc. Recent Developments
- 4.6 Protein Sciences Co.
- 4.6.1 Protein Sciences Co. Company Information
- 4.6.2 Protein Sciences Co. Business Overview
- 4.6.3 Protein Sciences Co. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Protein Sciences Co. Anti-Infective Vaccines Product Portfolio
- 4.6.5 Protein Sciences Co. Recent Developments
- 4.7 Organon Teknika Co.
- 4.7.1 Organon Teknika Co. Company Information
- 4.7.2 Organon Teknika Co. Business Overview
- 4.7.3 Organon Teknika Co. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Organon Teknika Co. Anti-Infective Vaccines Product Portfolio
- 4.7.5 Organon Teknika Co. Recent Developments
- 4.8 MedImmune LLC
- 4.8.1 MedImmune LLC Company Information
- 4.8.2 MedImmune LLC Business Overview
- 4.8.3 MedImmune LLC Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 MedImmune LLC Anti-Infective Vaccines Product Portfolio
- 4.8.5 MedImmune LLC Recent Developments
- 4.9 MassBiologics
- 4.9.1 MassBiologics Company Information
- 4.9.2 MassBiologics Business Overview
- 4.9.3 MassBiologics Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 MassBiologics Anti-Infective Vaccines Product Portfolio
- 4.9.5 MassBiologics Recent Developments
- 4.10 Intercell Biomedical
- 4.10.1 Intercell Biomedical Company Information
- 4.10.2 Intercell Biomedical Business Overview
- 4.10.3 Intercell Biomedical Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Intercell Biomedical Anti-Infective Vaccines Product Portfolio
- 4.10.5 Intercell Biomedical Recent Developments
- 4.11 ID Biomedical Co.
- 4.11.1 ID Biomedical Co. Company Information
- 4.11.2 ID Biomedical Co. Business Overview
- 4.11.3 ID Biomedical Co. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 ID Biomedical Co. Anti-Infective Vaccines Product Portfolio
- 4.11.5 ID Biomedical Co. Recent Developments
- 4.12 Emergent BioDefense Operations Lansing Inc.
- 4.12.1 Emergent BioDefense Operations Lansing Inc. Company Information
- 4.12.2 Emergent BioDefense Operations Lansing Inc. Business Overview
- 4.12.3 Emergent BioDefense Operations Lansing Inc. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Emergent BioDefense Operations Lansing Inc. Anti-Infective Vaccines Product Portfolio
- 4.12.5 Emergent BioDefense Operations Lansing Inc. Recent Developments
- 4.13 Diagnostics Ltd.
- 4.13.1 Diagnostics Ltd. Company Information
- 4.13.2 Diagnostics Ltd. Business Overview
- 4.13.3 Diagnostics Ltd. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Diagnostics Ltd. Anti-Infective Vaccines Product Portfolio
- 4.13.5 Diagnostics Ltd. Recent Developments
- 4.14 CSL Ltd.
- 4.14.1 CSL Ltd. Company Information
- 4.14.2 CSL Ltd. Business Overview
- 4.14.3 CSL Ltd. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 CSL Ltd. Anti-Infective Vaccines Product Portfolio
- 4.14.5 CSL Ltd. Recent Developments
- 4.15 Berna Biotech
- 4.15.1 Berna Biotech Company Information
- 4.15.2 Berna Biotech Business Overview
- 4.15.3 Berna Biotech Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Berna Biotech Anti-Infective Vaccines Product Portfolio
- 4.15.5 Berna Biotech Recent Developments
- 4.16 Barr Labs, Inc.
- 4.16.1 Barr Labs, Inc. Company Information
- 4.16.2 Barr Labs, Inc. Business Overview
- 4.16.3 Barr Labs, Inc. Anti-Infective Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Barr Labs, Inc. Anti-Infective Vaccines Product Portfolio
- 4.16.5 Barr Labs, Inc. Recent Developments
5 Global Anti-Infective Vaccines Market Scenario by Region
- 5.1 Global Anti-Infective Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-Infective Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Anti-Infective Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Anti-Infective Vaccines Sales by Region: 2027-2032
- 5.3 Global Anti-Infective Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Anti-Infective Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Anti-Infective Vaccines Revenue by Region: 2027-2032
- 5.4 North America Anti-Infective Vaccines Market Facts & Figures by Country
- 5.4.1 North America Anti-Infective Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-Infective Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Anti-Infective Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anti-Infective Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Anti-Infective Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-Infective Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Anti-Infective Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anti-Infective Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-Infective Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-Infective Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-Infective Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-Infective Vaccines Market Facts & Figures by Country
- 5.7.1 South America Anti-Infective Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-Infective Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Anti-Infective Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anti-Infective Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-Infective Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-Infective Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-Infective Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anti-Infective Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Anti-Infective Vaccines Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Anti-Infective Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-Infective Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Anti-Infective Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-Infective Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-Infective Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-Infective Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Anti-Infective Vaccines Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Anti-Infective Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-Infective Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Anti-Infective Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-Infective Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-Infective Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-Infective Vaccines Value Chain Analysis
- 8.1.1 Anti-Infective Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-Infective Vaccines Production Mode & Process
- 8.2 Anti-Infective Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-Infective Vaccines Distributors
- 8.2.3 Anti-Infective Vaccines Customers
9 Global Anti-Infective Vaccines Analyzing Market Dynamics
- 9.1 Anti-Infective Vaccines Industry Trends
- 9.2 Anti-Infective Vaccines Industry Drivers
- 9.3 Anti-Infective Vaccines Industry Opportunities and Challenges
- 9.4 Anti-Infective Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst